Insulin secretion by pancreatic β-cells is stimulated by glucose, amino acids, and other metabolic fuels. Glutamate dehydrogenase (GDH) has been shown to play a regulatory role in this process (1-3). The importance of GDH was underscored by features of the hyperinsulism/ hyperammonemia (HI/HA) syndrome where a dominant mutation causes the loss of inhibition by GTP and ATP (4-6). Here we report the effects of green tea polyphenols on glutamate dehydrogenase and insulin secretion. Of the four compounds tested, EGCG and ECG were found to inhibit the enzyme with nanomolar ED 50 's and therefore as potent as the physiologically important inhibitor, GTP. Furthermore, we demonstrate that EGCG inhibits BCH stimulated insulin secretion, a process that is mediated by GDH, under conditions where GDH is no longer inhibited by high-energy metabolites. EGCG does not affect glucose stimulated insulin secretion under high-energy conditions where GDH is probably fully inhibited.
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We further show that these compounds act in an allosteric manner independent of their antioxidant activity and that the β-cell stimulatory effects are directly correlated with glutamine oxidation. These results demonstrate that EGCG, much like the activator of GDH, BCH, can facilitate dissecting the complex regulation of insulin secretion by pharmacologically modulating the effects of GDH.
The mitochondria of the pancreatic β-cell play an integrative role in fuel stimulation of insulin secretion.
The current concept is that mitochondrial oxidation of substrates increases the cellular phosphate potential which is manifested by a rise in the ATP 4-/MgADP 2-ratio. This, in turn, closes the plasma membrane K ATP channels, opens voltage-gated Ca 2+ channels, causes a rise of free cytoplasmic Ca 2+ , and leads to insulin granule exocytosis.
Mitochondrial GDH catalyzes the oxidative deamination of L-glutamate and exhibits complex regulation in mammals through inhibition by palmitoyl CoA, GTP, and ATP, and activation by ADP and leucine (7) . The connection between GDH and insulin regulation was initially established using a nonmetabolizable analog of leucine (8, 9) , BCH (β-2-aminobicycle [2.2.1]heptane-2-carboxylic acid). These studies demonstrated that activation of GDH was tightly correlated with increased glutaminolysis. In addition, it has also been noted that factors that regulate GDH may affect insulin secretion (10) . It was suggested that glutamate serves as a mitochondrial intracellular messenger when glucose is being oxidized and that the GDH participates in this process by synthesizing glutamate (11) . However, the hypothesis that GDH, with a very high Km for ammonium, functions in the reductive amination reaction invivo is controversial (12) . Subsequently, we postulated that glutamine could also play a secondary messenger role and that GDH plays a role in its regulation (1, 2) .
The in-vivo importance of GDH in glucose homeostasis was demonstrated by the discovery that a genetic hypoglycemic disorder, the hyperinsulinemia/hyperammonemia (HI/HA) syndrome, is caused by dysregulation of GDH.
Therefore, allosteric regulation of GDH is central to understanding the response of the β-cell to the cellular fuel state. Children with HI/HA have increased β-cell responsiveness to leucine and susceptibility to hypoglycemia following high protein meals (13) . During glucose-stimulated insulin secretion, we have proposed that the generation of high energy phosphates inhibits GDH and promotes conversion of glutamate to glutamine which, alone or combined, may amplify release of insulin (1, 2) .
Our goal was to find a non-toxic pharmacological agent that could be used to test these models and assess whether GDH might be an appropriate target in the treatment of disordered glucose homeostasis.
To that end, naturally occurring compounds from green tea were examined. According to legend, green tea was discovered by the Chinese Emperor Shen-Nung in 2737 B.C. and for centuries has been used as a folk remedy to treat a number of ailments including diabetes mellitus.
Green tea is a significant source of a type of flavonoids called catechins: including epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC) (see figure 1 for the structure). One 200 ml cup of green tea supplies 140, 65, 28, and 17 mg of these polyphenols, respectively (14) . Over the past few decades, there has been growing interest in EGCG since it has been suggested to decrease cholesterol levels (15) , act as an antibiotic (16) and anticarcinogen (17) , repress hepatic glucose production (18) , and enhance insulin action (19) . The exact mechanism of action of EGCG with regard to these various effects is largely unknown and in many cases is assumed to be due to its antioxidant activity.
In this current study, we demonstrate that EGCG specifically and allosterically inhibits GDH and, in turn, affects insulin secretion by pancreatic β-cells. Kinetic analysis demonstrates that EGCG and ECG, but not EGC and EC, inhibit purified GDH with nanomolar ED 50 's. This inhibition is dependent upon the antenna-like protrusion on the enzyme but is unlikely to bind to the GTP inhibitory site since EGCG inhibits forms of GDH with non-functional GTP sites. Studies with pancreatic β-cells demonstrated that EGCG specifically affects insulin secretion under conditions where GDH is known to be important for glucose homeostasis.
These results demonstrate that, as has been the case with the activator of GDH, BCH, EGCG can be used as a pharmacological tool to examine the complex regulation of insulin secretion by specifically blocking GDH activity.
MATERIALS AND METHODS
Kinetic Analyses -The bovine GDH (bGDH) used in these studies was obtained as an aqueous (NH 4 ) 2 SO 4 suspension from Sigma Aldrich Chemical Company. Prior to kinetic analysis, aliquots of GDH were extensively dialyzed against 0.1M sodium phosphate buffer, pH 7.0, that contained 1 mM EDTA. Human wild type and mutant GDH was expressed in E. coli (20) and tGDH was purified from Tetrahymena (21) as previously described. The enzyme concentrations were adjusted to 1mg/ml and the amount of enzyme added to the reaction mixture was adjusted to yield optimal steady state velocity measurements.
All solutions were made immediately prior to use. Enzyme assays were performed by monitoring reduced coenzyme absorbance at 340nm using a Shamadzu UV-1601 spectrophotometer.
The reductive amination reactions were performed in 1 ml volumes at pH 7.0 in the presence of 0.1 mM NADH, 50 mM NH 4 Cl, and 5 mM 2-oxoglutarate. The rate of NADH oxidation was calculated using an extinction coefficient of 6.22mM -1 cm -1 .
Islets Isolation and Culture -Pancreatic islets were isolated from fed adult male Wistar rats by collagenase digestion and cultured in RPMI 1640 medium (glucose-free; Sigma). The culture medium was supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 50 µg/ml streptomycin, and islets were incubated at 37 °C in a 5% CO 2 /95% air humidified incubator. Islets were cultured with 10 mM glucose for 3 to 4 days.
Insulin Secretion by Perifused Islets -100 cultured rat islets were loaded onto nylon filters in a small chamber and perifused in a Krebs-Ringer bicarbonate buffer (115 mmol/liter NaCl, 24 mmol/liter NaHCO 3 , 5 mmol/liter KCl, 1 mmol/liter MgCl 2 , 2.5 mmol/liter CaCl 2 , in 10 mM HEPES, pH 7.4) with 0.25% bovine serum albumin at a flow rate of 2 ml/min. Perifusate solutions were gassed with 95% O 2 /5% CO 2 and maintained at 37 °C. Samples were collected every minute for insulin assay. Insulin was measured by radioimmunoassay.
Islets Perifusion and Oxygen Consumption
Measurement -Approximately 1000 isolated rat islets were cultured in 10 mM glucose for 3 days and perifused in a glass chamber. The perifusion apparatus consisted of a peristaltic pump, a water bath (37 0 C), a gas exchanger (artificial lung: media flowed through the thin-walled silastic tubing loosely coiled in a glass jar that contained 20% O 2 and 5%CO 2 balanced with N 2 ), and fraction collector (Waters Division of Millipore). All transfer lines were insulated.
Oxygen partial pressure was recorded every 10 seconds by phosphorescence lifetimes of an oxygen-sensitive porphyrin (palladium-mesotetra; 4-carboxyphenyl porphyrin dendrimer) (22) . The dye molecules were excited with pulses at 524 nm from a UV lead and emission was measured at 690 nm. The inflow oxygen tension was measured in the absence of islets in the chamber before and after each experiment.
The perifusate was a Krebs-Ringer bicarbonate buffer (pH 7.4) containing 1% bovine serum albumin equilibrated with 20% O 2 and 5% CO 2 balanced with N 2 . The flow rate was approximately 100 µl/min and samples were collected every 2 min for insulin measurements.
[U- 14 C]-glutamine Oxidation -Islets were cultured with 10 mM glucose for 3 days. Batches of 100 islets were preincubated with glucose-free KrebsRinger bicabonate buffer containing EGCG, EGC, or DON (6-diazo-5-oxo-L-norleucine) for 60 min. Islets were then incubated with 2 or 3 mM glutamine in the presence of BCH and EGCG, EGC or DON in accordance with the preincubation protocol, for another 60 min with 2 µCi [U-
14 C]-glutamine (NEN-Life Science Products, UK) present. A trap filter was placed in each tightly sealed glass tube to collect the 14 CO 2 produced by the islets, and the amount of radioactivity was determined by liquid scintillation counting.
[U- 14 C]-glucose oxidation -Islets were prepared as above and batches of 100 islets were preincubated with glucose-free Krebs-Ringer bicabonate buffer containing varying concentrations of EGCG for 60 min. Islets were then incubated with 3 mM and 12 mM glucose in the presence of EGCG for another 60 min with 2 µCi [U-
14 C]-glucose (NEN-Life Science Products, UK) present. Production of 14 CO 2 was monitored as described above.
RESULTS
Since green tea was suggested as a therapeutic agent for the treatment of diabetes more than 70 years ago (23) and because of the role that GDH plays in insulin secretion, the effects of green tea catechins on GDH were tested in-vitro. As shown in Figure 1 , EGCG and ECG, but not EGC or EC, are potent inhibitors of GDH activity with ED 50 's of ~300 nM. Since all four polyphenols have comparable antioxidant activities (24) , this strongly suggests that EGCG and ECG effects are allosteric in nature.
This inhibition is also reversible since dialysis of an EGCG/GDH mixture completely alleviated the inhibition (data not shown).
To further ascertain how EGCG inhibits the reductive amination reaction, the polyphenol was added to the reaction at various concentrations of NADH and 2-oxoglutarate ( Figure 2 ). As summarized in Table 1 , EGCG affects both the slope and the Y-intercept of the curves in a manner consistent with non-competitive inhibition. These results suggest that EGCG does not act by directly competing with either coenzyme or substrate binding to the active site and that it inhibits by binding to either the free enzyme or the enzyme-substrate complex.
To examine how EGCG interacts with other allosteric regulators, the ability of the activators BCH, leucine, and ADP to reverse EGCG was examined. Figure 3 displays the data in two different ways. On the left, the raw velocities of the reactions are shown in the presence and absence of EGCG at varying concentrations of the activators. On the right, the same data is plotted as a percent of the velocity of the reaction compared to the reaction rate in the absence of activators in the presence or absence of EGCG. Under these assay conditions, and in the absence of EGCG, all three activators only increase the velocity of the reactions by at most 30%. However, in the presence of 1µM EGCG, all three regulators can by guest on November 15, 2017 http://www.jbc.org/ Downloaded from activate the reaction by as much as three-fold. In absolute terms, the addition of 1 µM EGCG decreased GDH activity to ~20% that of the uninhibited enzyme. In all cases, the activators partially alleviated EGCG inhibition and increased the enzymatic activity to ~60% that of the uninhibited enzyme. This is very similar to previous studies that have shown that ADP and leucine activate by binding to spatially different sites (25) and can have apparently greater activation if an allosteric inhibitor is present (e.g. GTP). Abrogation of EGCG inhibition by these allosteric activators supports the above contention that EGCG acts in an allosteric manner.
The HI/HA syndrome is caused by the loss of GTP inhibition of GDH (3).
Many of the mutations lie in the GTP binding site and likely act by sterically interfering with GTP binding (6, 20, 26, 27) . Therefore, EGCG, or compounds that specifically target GDH, could be therapeutically useful if it also inhibited the HI/HA mutant forms of GDH. To this end, EGCG was tested against five different HI/HA mutant forms of GDH ( Figure 4 ) and was found to have the same efficacy as with wild type human GDH. In addition, EGCG inhibited GDH from Tetrahymena thermophilia (tGDH) that, like these HI/HA mutants, is not regulated by GTP (21) . These results suggest that EGCG acts independent of the GTP inhibitory site. From our previous structural analyses, mammalian GDH has a 48 residue 'antenna-like' feature protruding from the top of each of its six subunits (27, 28) that is necessary for ADP, GTP, and palmitoyl CoA regulation (21) . As shown in figure 4, EGCG does not inhibit the 'antenna-less' form of human GDH. This demonstrates that EGCG inhibition of GDH is unrelated to antioxidant activity of the flavonoids, does not directly affect the active site, and is dependent upon the antenna structure to exert its activity.
Since EGCG was found to be a potent inhibitor of GDH in-vitro, it was postulated that GDH-dependent β-cell functions should also be influenced by these catechins. For example, the phenomenon of leucine stimulated insulin secretion (LSIS) has been recently elucidated by our studies showing that LSIS is mediated by GDH and its regulation of glutamineolysis (1) . LSIS is only observed after a prolonged period of run-down to produce a state of energy depletion.
Under these conditions, the levels of GDH inhibitors, ATP and GTP, are reduced while the concentration of the GDH activator, ADP, is increased. When leucine (or its non-metabolizable analog, BCH) is then added to cells in this depleted state, the flux of glutamine through glutaminase and GDH is increased, ATP is generated, and the β-cells are stimulated to secrete insulin.
As shown in figure 5 , the BCH stimulation of insulin secretion is blocked by EGCG, but not EGC, in a dose-dependent manner with an ED 50 of less than 10 µM. EGCG does not affect the intrinsic ability of the cells to secrete insulin, since depolarization by KCl still resulted in release of insulin. The concentration of EGCG required to abrogate LSIS is significantly higher than what is necessary to inhibition GDH in-vitro. This is likely due to the bioavailability of EGCG in the mitochondria and/or that higher levels of EGCG are required in tissue to overcome antagonism by leucine, ADP, and BCH.
According to our working model, the effects of EGCG on BCH stimulated insulin secretion (BCH-SIS) are due to a block of glutamine oxidation through GDH (1). To test for this, the effects of EGCG and EGC on BCH-SIS were measured while simultaneously monitoring respiration rates. As shown in figure 6 , EGCG strongly inhibited both BCH-SIS and the BCH induced increase in respiration rates. The addition of EGCG itself does not have any significant effect on oxygen consumption in the absence of BCH. EGC has a number of interesting effects on BCH-SIS. Firstly, it does not cause significant inhibition of BCH-SIS nor does it have as strong of an effect on respiration as EGCG. Secondly, EGC seems to cause a slight sensitization of the β-cells to BCH as manifested in a slightly faster response to BCH-mediated insulin secretion and respiration enhancement. This clearly demonstrates that the EGCG effects are not due to the catechin antioxidant activity and suggests that EGC may have some, albeit quite different, effects on the pancreatic cells.
According to the working model (1,2), it was predicted that EGCG would block BCH-SIS by inhibition of GDH-mediated glutaminolysis. To directly test for this, the effects of EGCG on BCH stimulation of glutamine oxidation were measured ( figure 7A glutaminolysis. EGCG inhibition of glutamine oxidation occurs in a dose-dependent manner with maximal effects occurring at ~20µM and never decreasing glutamine oxidation below that of the cells not stimulated by BCH ( Figure 7B ). As shown in figure 7C , this is in contrast to the effects of 6-diazo-5-oxo-L-norleucine (DON), an inhibitor of glutaminase, that blocks glutaminolysis to levels lower than the unstimulated β-cells at high concentrations. These results are summarized in figure 7D and demonstrate that EGCG does not have an effect on basal levels of glutamine oxidation but does block BCH enhancement of glutaminolysis. Together with the enzymatic data, it is clear that EGCG effects on BCH-SIS are due to inhibition of GDH.
Since our previous studies had suggested that glutamine is an important signaling molecule for glucose stimulated insulin secretion (GSIS) (2), it was then necessary to determine whether EGCG might also affect GSIS. Islets were incubated for three days in the presence of 20 mM ( Figure 8A ) or 10 mM ( Figure 8B ) glucose, then perifused for 50 min in the absence of glucose +/-catechins, and then subjected to a glucose ramp. In all cases, neither EGC nor EGCG affected GSIS under these short run-down conditions. As confirmation of this, insulin secretion and oxygen consumption were measured during glucose stimulation ( Figure  9 ). It is clear that EGCG does not affect respiration under these conditions. Finally, as shown in figure 10 , EGCG does not affect glucose oxidation over a wide range of EGCG concentrations when the islets are incubated in either 3 mM or 12 mM glucose. Therefore, the catechins do not, in and of themselves, affect cellular respiration, glucose oxidation, or insulin secretion.
Rather, these results support the contention that EGCG affects insulin secretion via modulation of GDH activity. Under the brief rundown conditions used for the GSIS analysis, the levels of high-energy metabolites (GTP and ATP) have not been depleted and these effectively shut down GDH activity (1, 2, 29) . Therefore, additional inhibition by EGCG does not affect glutamate/glutamine levels nor does it, in turn, affect GSIS under these conditions.
DISCUSSION
The data presented here clearly demonstrate that EGCG allosterically inhibits GDH in-vitro with a nanomolar ED 50 . Since this inhibition is observed with EGCG and ECG but not EC or EGC, inhibition cannot be due to the anti-oxidant property of these catechins. EGCG inhibition is apparently non-competitive and, similar to GTP inhibition, is abrogated by leucine, BCH, and ADP. It is unlikely that EGCG acts by binding to the GTP site since HI/HA GDH mutants and tGDH are all inhibited by EGCG but have inactive GTP binding sites. EGCG inhibition is apparently dependent upon the antenna since the an 'antennaless' mutant of GDH is also unaffected by EGCG. This was also found to be the case with ADP activation and GTP inhibition (21) .
This specificity of EGCG for GDH inhibition was mirrored in studies on β-cells and demonstrates the importance of GDH in the regulation of insulin secretion. Our previous studies have demonstrated that GDH plays a major role in LSIS by controlling glutaminolysis (1,2). Therefore it was not unexpected that EGCG, by inhibiting GDH activity, abrogates BCH-SIS. The specificity of this inhibition was confirmed by demonstrating that EGCG, but not EGC, causes a concomitant blockade of glutaminolysis stimulated by BCH but not in the basal level of glutamine oxidation or cellular respiration. When EGCG is added to β-cells during glucose stimulation under conditions that GDH is known to not play a major role in the regulation of insulin secretion, no effect is observed on insulin secretion, glucose oxidation, or cellular respiration. It is worthy of note that this study is limited to using BCH to stimulate GDH to avoid the oxidation of leucine being involved in the process of insulin secretion and complicating the interpretation of experiments.
Together, the data presented here clearly demonstrate that EGCG can affect BCH-SIS by inhibiting GDH activity in a manner that is consistent with our working hypothesis as summarized in figure 11 . The foundation of this model is that GDH can regulate insulin secretion by controlling the intracellular pool of glutamine and/or glutamate.
In the case of BCH-SIS, the β-cell is depleted of glucose and provided with glutamine at low concentration levels prior to the application of BCH. Therefore, when BCH is applied, the lack of ATP/GTP inhibition combined with ADP and BCH activation facilitates glutaminolysis. This leads to the generation of ATP and, combined with the exogenously added glutamine that may act as an intracellular signal, insulin secretion is facilitated.
EGCG inhibits GDH, blocks glutaminolysis, and thereby prevents the BCH effects.
In the case of GSIS, the effects of EGCG are likely dependent upon the energy state of the cell. When the β-cell has been run-down for a brief period of time, glutaminolysis is not the main energy source for the cell and high-energy metabolites (GTP and ATP) are still present at high enough levels to inhibit GDH activity. Under these conditions, EGCG does not affect GSIS since GDH is already effectively inhibited.
Further, these results demonstrate that EGCG does not intrinsically affect insulin secretion.
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